Ignite Creation Date:
2024-05-06 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05271318
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2022-02-04
Brief Title:
Oncolytic Adenovirus Coding for TNFa and IL2 TILT-123 With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer
Sponsor:
TILT Biotherapeutics Ltd
Organization:
TILT Biotherapeutics Ltd
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin andor Cisplatin |
| Platinum-refractory Ovarian Carcinoma |
| Platinum-resistant Ovarian Cancer |
| Platinum-Resistant Fallopian Tube Carcinoma |
| Platinum-Resistant Primary Peritoneal Carcinoma |
| Platinum-Refractory Fallopian Tube Carcinoma |
| Platinum-Refractory Primary Peritoneal Carcinoma |
| Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin andor Cisplatin |
| Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin andor Cisplatin |